Navigation Links
Indevus Announces Allergan as New Partner for SANCTURA Brand
Date:9/19/2007

Company Enters Into License, Commercialization and Supply Agreement Company to Host Conference Call at 12:30 p.m. Eastern Time, September 19,

2007

LEXINGTON, Mass., Sept. 19 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that Allergan, Inc. (NYSE: AGN), through its acquisition of Esprit Pharma, has obtained the United States rights to SANCTURA(R) and SANCTURA(R) XR. In connection with Allergan's acquisition of Esprit Pharma, Indevus has executed an amended and restated license, commercialization and supply agreement with Esprit Pharma that will be effective, with certain exceptions, on the closing of the acquisition. The acquisition of Esprit Pharma is expected to be completed by the end of October 2007. The Company will host a conference call and webcast today at 12:30 p.m. eastern time (details follow below).

"We are extremely pleased to see SANCTURA XR now in the hands of a company with the resources and experience to maximize what we believe is a class- leading opportunity" said Glenn L. Cooper, M.D., chief executive officer and chairman of Indevus. "Allergan has a proven record of success in marketing specialty pharmaceuticals, and with their leadership I am quite optimistic that SANCTURA XR will be in a strong position to achieve its full potential. We look forward to working with Allergan over the coming months to prepare for a successful launch of SANCTURA XR and upon launch, to
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... of patented university inventions licensed to biotechnology firms ... commercialization. To open these roadblocks, the researchers suggest ... the discovery stage could lead to faster commercialization ... derived from discoveries made in university laboratories and ... during clinical trials, which have a high failure ...
(Date:8/20/2014)... , Aug. 20, 2014 Neurotrope, Inc. ... a conference call to provide an update on ... Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. and Canada) ... web cast: www.neurotropebioscience.com , under "Investor Relations"The teleconference ... completion through September 2, 2014 at (888) 203-1112 ...
(Date:8/20/2014)... International Corporation (NASDAQ: PRXL ) announced today ... Conference in New York.  Ingo Bank , Senior ... a presentation on PAREXEL and discussing business developments at ... A live webcast of the discussion will be ... www.PAREXEL.com in the Upcoming Events portion of ...
(Date:8/20/2014)... 20, 2014 /PRNewswire-iReach/ -- A case study from ... the school,s bioengineering department and the Intel® Internet ... Software Academic Program, UCSD,s research focuses on exploring ... body.  Photo - http://photos.prnewswire.com/prnh/20140819/137540 ... work of Dr. Todd P. Coleman , ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Neurotrope To Host Conference Call 2PAREXEL International To Present At Baird Healthcare Conference 2Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2
... UCB, Inc. and the Crohn,s Disease Working Group (CDWG) today ... Inflammatory Bowel Disease (IBD) for Gastroenterology (GI) Fellows, who each ... or basic research, totaling $175,000 for all four grants. The ... awards were funded by a grant from UCB. A ...
... Therapeutics, Inc. (PTC) today announced that Clare Kennedy has ... In this role, she will report to Theresa Natalicchio, ... PTC,s patient services and distribution functions focusing on product ... http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO ) , , ...
... , - Results from a randomized Phase ... Meeting -, , , MISSISSAUGA, ON, June 1 /PRNewswire-FirstCall/ ... AIM:YMBA), a life sciences product development company that identifies and ... stages of development, today reported that results from a randomized ...
Cached Biology Technology:UCB and Crohn's Disease Working Group Award $175,000 in Research Grants to Gastroenterology Fellows 2PTC Therapeutics Appoints Clare Kennedy as Vice President of Commercial Operations 2NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 2NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 3NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 4NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 5NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 6NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 7NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS 8
(Date:8/20/2014)... 2014  The second annual Biometrics UnPlugged Executive ... Tampa, Florida on September 15, 2014, ... Technology and Strategy at Samsung, and Philippe de ... of this year,s event is Mobility at the ... "Biometrics UnPlugged: Mobility at the Crossroads of Commerce ...
(Date:8/19/2014)... in supermarkets to encourage healthier spending habits? A new ... very question by tracking the purchasing records in a ... rate the nutritional value of foods for sale. , ... Just, PhD, and Brian Wansink PhD, author of Slim ... 150 Hannaford Supermarkets in the Northeastern United States between ...
(Date:8/19/2014)... a lemur. It,s not an African Bush Baby or even ... and downright "cool" primate from Southeast Asia. , "It,s really ... Rafe Brown, curator-in-charge at the University of Kansas, Biodiversity Institute. ... furry body; a long tail with a furry tuft at ... look a bit like the disks on the digits of ...
Breaking Biology News(10 mins):Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3
... an unlikely new target: molecules. Scientists at the National ... of molecular data similar to Facebook,s recently debuted graph ... to find all their New York-living, beer-drinking buddies in ... rapidly sift through enormous chemical and biological data sets ...
... July 18, 2013 -- Scientists at Wake Forest Baptist Medical ... effect of impacts to the head incurred by football players. ... capture players, exposure to the risk of concussion over the ... magnitude of all impacts, said senior author of the study ...
... Health Summit held at the Mayflower Renaissance hotel in Washington ... to scientists, writers and researchers looking to learn and discuss ... links mushrooms to today,s and future health issues. ... world,s top scientists, researchers and nutrition experts who will provide ...
Cached Biology News:Facebook for molecules 2Facebook for molecules 3Scientists develop new way to measure cumulative effect of head hits in football 2Scientists develop new way to measure cumulative effect of head hits in football 3
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Rabbit polyclonal to TAB1 ( Abpromise for all tested applications). entrezGeneID: 10454 SwissProtID: Q15750...
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Chicken polyclonal to HADHSC - Azide free ( Abpromise for all tested applications). Antigen: Amino acids 57-314 of HADHSC Entrez GeneID: 3033 Swiss Protein ID: Q16836...
Biology Products: